SynthesisFrontiers in pharmacology2025
Efficacy of Xiaoyao-san preparations in treating Hashimoto's thyroiditis: a meta-analysis and systematic review.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic and Clinical Perspectives on Traditional Chinese Medicine in Thyroid Cancer Management.Biomolecules & therapeutics · 2026Review
- Hashimoto's thyroiditis: from pathogenesis to clinical management.Frontiers in endocrinology · 2026Review
- Exploring the Comprehensive Treatment of Hashimoto's Thyroiditis with Traditional Chinese Medicine from the Perspective of Modern Medicine.Therapeutics and clinical risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess Xiaoyao-san (XYS) preparations' effectiveness in treating Hashimoto's thyroiditis. Methods: Eight databases were searched for randomized controlled trials (RCTs) comparing XYS preparations to a low-iodine diet (LID), selenium yeast (SY), levothyroxine (LT4), or Results: This study analyzed seven randomized controlled trials involving 612 patients. Meta-analysis demonstrated that XYS preparations significantly reduced TPOAb levels [SMD = -0.74, 95% CI (-1.02, -0.46), Conclusion: Combination therapy with XYS preparations and LT4 may reduce TPOAb, TgAb, and TSH levels in HT patients. XY combined with LID or SY therapy is more effective at restoring FT3 and FT4 levels. While XYSJW outperforms OS preparations in lowering TgAb levels, it may not surpass OS in restoring thyroid hormone levels. Most studies reviewed are of low quality. XYS preparations appear to modulate cytokines by targeting immune markers and reducing inflammation, but their safety profile remains unclear, requiring further robust evidence. Systematic Review Registration: clinicaltrials.gov, identifier CRD42023472233.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.